TRANSDERMAL DELIVERY OF AZATADINE

Abstract: Compositions for the transdermal delivery of azatadine and the use of such composition in the treatment of allergic reactions.

Description: TRANSDERMAL DELIVERY OF A2ATADINE This invention relates to the use of azatadine or a salt thereof in pharmaceutical compositions suitable for transdermal delivery, to such transdermal compositions containing azatadine or its salt and to the treatment of allergic' reactions by transdermal application of azatadine or a salt thereof. In recent years, various drug delivery systems have been developed which provide sustained release therapy via a sub-dermal insert. Systems have been disclosed which also provide drug delivery systems suitable for transdermal drug administration. U.S. Pat. No. 4,336,243 discloses a transdermal delivery pad for nitroglycerin administration, nitroglycerin dispersion and transport. The use of transdermal drug delivery systems produces more controlled blood levels, lower frequency of dosing and enhanced patient compliance. Further, the transdermal delivery of an antihistamine to treat various allergic reactions is most desirable for reasons of conveninence and effectiveness. Unfortunately, however, until now no antihistamine seemed to possess the properties necessary in order to be effective in a transdermal drug delivery system. These properties are high potency, proper physico-chemical characteristics, good dermal penetration and, lack of dermal irritation and/or sensitization. Quite unexpectedly, azatadine has been found to possess all of the above described properties which are necessary for being effective in a transdermal drug delivery system. Frequently, in order to obtain effective dermal penetration of drugs in a transdermal delivery system, a promoter such as dimethyl sulfoxide is used. It is unexpected that azatadine's transdermal effectiveness is not dependent on the use of such a promoter. Azatadine, 6,ll-dihydro-ll-(1-methy1-4- piperidylidene)-5_H-benzo[5,6]cyclophepta[1,2-b] pyridine is known as a potent antihi-stamine which is recognized as clinically effective for treating various allergic reactions but until now it has only been applied by the oral route. The invention sought to be patented in its method aspect is a pharmaceutical method for treating allergic reactions in a mammal which comprises the transdermal application of an effective amount of azatadine combined with a pharmaceutically acceptable transdermal carrier. -3- The invention sought to be patented in a transdermally acceptable pharmaceutical dosage formaulation and or composition, comprises an effective amount of azatadine in combination with a pharmaceutically acceptable transdermal carrier. Preferably, the transdermally acceptable composition is utilized to prepare a "resevoir type" or "matrix type" patch which is applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of azatadine through the skin. Most preferably, the patch of the invention will be worn for a period of about 24 hours and provide a total daily dosage of about 0.5 mg to about 1.5 mg of azatadine. The patch may then be replaced if necessary with a fresh patch, thereby providing a constant blood level of azatadine to the patient in need thereof. Azatadine and the preparation thereof are described in U.S. Patent 3,326,924. Pharmaceutically acceptable salts of azatadine such as the aleate, sulfate, succinate and acetate salts may also be prepared as described therein and these are equivalent to azatadine for purposes of the invention. A preferred pharmaceutically acceptable salt of azatadine is the maleate salt. Azatadine, is an orally acceptable antihista ine currently approved for sale in the United States and other countries of the world for use in the treatment of allergic disorders such as uritcaria, seasonal rhinitis and pollen sensitivity. In an attempt to find a transdermally effective antihistamine, various known antihistamines were evaluated for their dermal irritation and dermal penetration properties. The results of these evaluations are in Table 1. The irritation results are reported as either irritating (+) or non-irritating (-), and the penetration results are reported as either good (+) or poor (-). Some antihistamines listed were not tested for in vitro dermal penetration and these are indicated as. Table 1 Transdermal Application of Antihistamines Rabbit In Vitro Dermal Dermal Compound Irritation a * Penetrati Chlorphenira ine base (patch) (+) (+) Chlorpheniramine maleate (20%) (-) (-) Chlorpheniramine succinate (20%) (-) (-) Chlorpheniramine sulfate (20%) (-) (- ' ) Chlorpheniramine acetate (20%) (+) (+) Chlorpheniramine palraitate (20%) (+) (+) Pheniramine base (20%) (-) Dexbroraphenirara ne (1 %) (+) Dexchlorpheniramine base (+) Azatadine (-) (+) Doxylamine succinate (+) Diphenhydramine HCl (+) Triprolidine HCl (+) Diphenylpyraline HCl (+) Cyprhoheptadine HCl (+) Promethazine HCl (+) Carbinoxamine maleate (+) Di ethindine maleate (+) a "Results of a 24/72 hour (no irritation seen for the first 24. hours) dermal irritation screen in rabbits with intact skin. SCRESNING OP ANTBIHISTAMINB FOR DERMAL IRRITATION Eight young adult New Zealand white rabbits were assigned to two groups. The rabbits were housed in stainless steel cages and maintained under standard laboratory conditions. Each cage was identified with a color coded label indicating the test substance, rabbit number, sex, and study number. Food and water were supplied ad libitum. On the day of dosing, the back of each rabbit was clipped free of hair. The test sub¬ stance, a 20% azatadine cream formulation, or a placebo cream was instilled into two Hill Top Chambers and affixed one on each side of the midline of the back. To prevent removal, the chambers were covered with an orthopedic stockinette and secured by a canvas coat. Signs of dermal irritation graded on the basis of criteria presented in Draize, J. H; Dermal Toxicology, An Appraisal Of The 'Safety And Chemical In. Food Drugs & Comestics j The Association of Food & Drug Officials of the United States 1959 pp 46-59, were recorded after removal of the chambers at 24 and 72 hours. SCREENING OF ANTIHISTAMINES FOR DERMAL PENETRATION The skin penetration assembly used was similar to that described by Franz (J. Invest. Derm., 64:190, 1975). Excised defatted human skin was stretched across a resevoir containing a phosphate buffer solution (pH 7.4, 0.02M) in direct contact with the dermal side of the skin. The temperature of this buffer solution was maintained at 37^0.5'C by circulating water at the appropriate temperature through a jacket which surrounds each assembly. Freshly made preparation was applied to the stratum corneum surface. The buffer solution was removed in its entirety and replaced with fresh solution -7- at various time intervals and assayed for azatadine content. Several antihistamines were eliminated from consideration as effective transdermal drugs because they were shown to be dermal irritants. Another group of antihistamines, though they showed no dermal irritation, did not show dermal penetration, the latter property being an essential requirement for the effectiveness of a transdermal drug. The results given in Table 1 reveal that usually antihistamines which give positive results for dermal penetration are unacceptable for transdermal applications because of their dermal irritatant properties. It is surprising to find that after numerous antihistamines were tested, there was only one antihist¬ amine, azatadine, that had good dermal penetration and no dermal irritation and/or sensitization. Thus, the results in Table 1 show that of the compounds tested for transdermal application, only azatadine possess the characteristics necessary for transdermal use. The use of a particular transdermal formulation is not critical to the practice of the invention. Thus, the invention contemplates the use of any formulation, including those not yet discovered or fully characterized, so long as said transdermal dosage form can be utilized to transdermally deliver the desirable amount of azatadine. It is of interest to the practice of the present invention that the total daily dosage (through the skin) of azatadine which is administered by the transdermal formulation may be less than the currently recommended clinical daily administered dose by the oral route. Moreover, it is anticipated that upon implementive of the invention the azatadine blood levels will be more consistent and controlled than those obtained upon oral administration of the drug. However, this is not a requirement of the invention. This feature is anticipated in view of clinical experience with other trandermal drugs. Thus, the total daily transdermal dosage of azatadine when administered in a patch is expected to be from about 0.2 mg to about 5.0 mg, with 0.5 mg to about 1.5 mg being preferred. The particular dosage may be varied depending on the size and age of the patient and may also depend upon the severity of the condition being treated. Such dosage modification is within the skill of the clinical arts. The utilization of this new dosage form and its prescribed regimen will provide the recognized clinical efficacy of azatadine, having the advantages described above. Other frequencies of dosage application are anticipated, for example, a once every 3 day frequency or a once every 7 day frequency. Although a once a ' day dosage regimen may be preferred, it is not intended that the invention be limited to any particular regimen. Table 2 contains in vitro skin diffusion flux results obtained using human cadaver skin in a Franz diffusion cell, for a 1 cm* area,flux is defined as the amount of drug that traverses skin over time for a specified area. -9- Table 2 Accumulative Azatadine (mg/per cm 2 ) Formulation 3 20 Hr 45 Hr 72 Hr Ointment A 2.10 7.54 13.83 Ointment B 3.24 10.16 17.38 Cream 3.01 13.69 27. 1 Gel 2.38 7.11 11.79 Prepared in Examples 1-4, respectively This data (Table 2) indicates that azatadine traverses human skin in amounts which are clinically effective. The transdermal dose for clinical effectiveness is expected to be 1 mg/day. Azatadine flux rates of greater than 1 mg day (the preferred daily clinical dosage) were achieved within 20 hours for all of the formulation evaluated (Table 2). Those flux rates achieved a steady-state level between 20-45 hours post patch application. Moreover, these high flux rates were achieved without the use of proraotants (eg dimethyl sulfoxide). The following examples* illustrate formulations of azatadine that show good dermal penetration. Ξxample 1 Ointment A mg/g Azatadine 200 White Petrolatum 800 Example 2 Ointment B »_/_.. Azatadine 200 Propylene glycol 200 White Petrolatum 600 Example 3 Cream mg/g Azatadine 200 Mineral Oil 48 White Petrolatum 120 * Cetostearyl Alcohol 57.6 Polyethylene glycol 1000 18.0 monocetylether Propylene glycol 80 Wafer 476.4 Example 4 Gel mg/g Azatadine 200 Pluronic F-127 250 Ethanol 200 Water 350 Example 5 Patch mg/g Azatadine 100.00 Mineral Oil 54.0 White Petrolatum 135.0 Ceteryl Alcohol 65.0 Ceteth 20 20.0 Propylene Glycol 100.0 Water q.s. ad 1.0 g The formulations of examples 1-5 can be packaged to produce a "reservoir type" transdermal patch with or without a rate-limiting patch membrane. The size of the patch and or the rate limiting membrane can be chosen to deliver the transdermal flux rates desired. Alternatively, azatadine and/or its salts can be formulated into a "matrix-type" transdermal patch as in examples 5 and 6. Drug Delivery Systems Characteristics and Biomedical Application, R.L. Juliano, ed., Oxford University Press, N.Y. (1980); and Controlled Drug Delivery Vol. I Basic Concepts, Stephen D. Bruck (1983) describe the theory and application of methods useful for transdermal delivery sytems. The relevant teachings of these texts are herein incorporated by reference. The drug-matrix could be formed utilizing various ' polymers, e.g. silicone, polyvinyl alcohol, polyvinyl chloride-vinyl acetate co- polymer. The "drug matrix" may then be packaged into an appropriate transdermal patch. Example 6 Patch _τ___l Azatadine 200 silicone polymer 800 Example 7 Patch mg/g Azatadine 300 Polyvinyl chloride vinyl acetate co-polymer 700 The invention also contemplates a package which contains a specific number of transdermal patches that may be utilized to complete a specified course of treatment. For example, a package containing 7, 24 hours patches would be utilized to complete a one week course of therapy.

Claims: Claims 1. Transdermally effective topical anti-allergic pharmaceutical compositions comprising, as an active ingredient, azatadine or a salt thereof in combination with pharmaceutically acceptable transdermal carriers. 2. Composition according to claim 1 which is formulated as an ointment. 3. An ointment according to claim 2 which comprises 200 mg of azatadine and 800 mg of white petrolatum. 4. An ointment according to claim 2 which comprises 200 mg of azatadine, 200 mg of propylene glycol and 600 mg of white, petrolatum. 5. Composition according to claim 1 which is formulated as a cream. 6. A cream according to claim 5 which comprises 25-250 mg azatadine, 25-100 mg mineral oil, 50-200 mg white petrolatum, 30-100 mg cetearyl alcohol, 10-50 ceteth 20, 50-200 mg propylene glycol and water, the quantities of the ingredients being selected so that it gives a total of 1 g. 7. A cream according to claim 6 which comprises 100 mg azatadine, 54 mg mineral oil, 135 mg white petrolatum, 65 mg cetearyl alcohol, 20 mg ceteth 20, 100 mg propylene glycol and water to make a total weight of 1 g. 8. A cream according to claim 5 which comprises 200 mg of azatadine, 48 mg of mineral oil, 120 mg of white petrolatum, 57.6 mg of cetostearyl alcohol, 18 mg of polyethylene glycol 1000 monocetyl ether, 80 mg of propylene glycol and 476.4 mg of water. 9. Composition according to claim 1 which is formulated as a gel. 10. Gel defined according to claim 8 which comprises 200 mg of azatadine, 250 mg of pluronic F- 127, 200 mg of ethanol and 350 mg of water. 11. Composition according to claim 1 in the form of a patch. 12. The use of azatadine in combination ' with pharmaceutically acceptable transdermal carriers in topical transdermal treatment of allergic disorders.

Inventors: SEQUEIRA JOEL AUGUST, SEQUEIRA, JOEL, AUGUST
Applicants: SCHERING CORP, SCHERING CORPORATION
Application year: 1985
Main classification: A61K31
IPC codes: A61K9, A61K31